8-K

                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                ----------------

                                    FORM 8-K

                                 CURRENT REPORT
                       PURSUANT TO SECTION 13 OR 15(D) OF
                       THE SECURITIES EXCHANGE ACT OF 1934


Date of Report (Date of earliest event reported)   January 2, 2007
                                                   ---------------


                                ICU MEDICAL, INC.

             (Exact name of registrant as specified in its charter)

           DELAWARE                     0-19974                  33-0022692
           --------                     -------                  ----------
(State or other jurisdiction    (Commission File Number)     (I.R.S. Employer
      of incorporation)                                     Identification No.)


951 Calle Amanecer, San Clemente, California                       92673
- --------------------------------------------                       -----
  (Address of principal executive offices)                       (Zip Code)

                                 (949) 366-2183
                                 --------------
               Registrant's telephone number, including area code


                                       N/A
                                       ---
          (Former name or former address, if changed since last report)

     Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

     |_| Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)

     |_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)

     |_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))

     |_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))




                    INFORMATION TO BE INCLUDED IN THE REPORT


Item 1.01      Entry into a Material Definitive Agreement
               ------------------------------------------

               The Registrant agreed as of January 2, 2007 to settle an action
               against its former attorneys, Fulwider Patton Lee & Utecht, LLP.
               The Registrant will be paid $8 million in settlement of its
               claims against Fulwider.

Item 9.01      Financial Statements and Exhibits
               ---------------------------------

         (c)   Exhibits

         99.1  Press release, dated January 2, 2007 entitled, "ICU Medical, Inc.
               Reports Settlement of Litigation Against Former Attorneys".


                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.

Date:  January 3, 2007

                                        ICU MEDICAL, INC.



                                        s/ Francis J. O'Brien
                                        ---------------------
                                        Francis J. O'Brien
                                        Secretary, Treasurer and
                                        Chief Financial Officer

EX-99.1

                                                                    Exhibit 99.1


[GRAPHIC OMITTED] ICU MEDICAL, INC.


   ICU MEDICAL, INC. REPORTS SETTLEMENT OF LITIGATION AGAINST FORMER ATTORNEYS

SAN CLEMENTE, CALIF., JANUARY 2, 2007/PRNEWSWIRE-FIRSTCALL/ICU MEDICAL, INC.,
(Nasdaq:ICUI), a leading low cost manufacturer of safe medical connectors,
custom medical products and critical care devices, today announced that it had
reached an agreement to settle an action against Fulwider Patton Lee & Utecht,
LLP under which the Company alleged that during the course of its representation
of the Company and continuing thereafter, Fulwider engaged in various matters
for the Company's direct competitors, and committed other acts of negligence and
breaches of the attorney-client relationship. Fulwider did not admit any
liability or wrongdoing. The Company will be paid $8 million in settlement of
its claims against Fulwider.


    Contact:  Francis J. O'Brien
              Chief Financial Officer
              ICU Medical, Inc.
              (949) 366-2183

              John F. Mills
              Senior Managing Director
              Integrated Corporate Relations
              (310) 954-1100